|
1
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Chen W, Zheng R, Baade PD, Zhang S, Zeng
H, Bray F, Jemal A, Yu XQ and He J: Cancer statistics in China,
2015. CA Cancer J Clin. 66:115–132. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Travis WD, Brambilla E, Nicholson AG,
Yatabe Y, Austin JHM, Beasley MB, Chirieac LR, Dacic S, Duhig E,
Flieder DB, et al: The 2015 world health organization
classification of lung tumors: Impact of genetic, clinical and
radiologic advances since the 2004 classification. J Thorac Oncol.
10:1243–1260. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Herbst RS, Heymach JV and Lippman SM: Lung
cancer. N Engl J Med. 359:1367–1380. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Hecht SS: Tobacco carcinogens, their
biomarkers and tobacco-induced cancer. Nat Rev Cancer. 3:733–744.
2003. View
Article : Google Scholar : PubMed/NCBI
|
|
6
|
Thun MJ, Hannan LM, Adams-Campbell LL,
Boffetta P, Buring JE, Feskanich D, Flanders WD, Jee SH, Katanoda
K, Kolonel LN, et al: Lung cancer occurrence in never-smokers: An
analysis of 13 cohorts and 22 cancer registry studies. PLoS Med.
5:e1852008. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Thun MJ, Henley SJ and Calle EE: Tobacco
use and cancer: An epidemiologic perspective for geneticists.
Oncogene. 21:7307–7325. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Sun S, Schiller JH and Gazdar AF: Lung
cancer in never smokers-a different disease. Nat Rev Cancer.
7:778–790. 2007. View
Article : Google Scholar : PubMed/NCBI
|
|
9
|
Li S, Li L, Zhu Y, Huang C, Qin Y, Liu H,
Ren-Heidenreich L, Shi B, Ren H, Chu X, et al: Coexistence of EGFR
with KRAS, or BRAF, or PIK3CA somatic mutations in lung cancer: A
comprehensive mutation profiling from 5125 Chinese cohorts. Br J
Cancer. 110:2812–2820. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Cai X, Sheng J, Tang C, Nandakumar V, Ye
H, Ji H, Tang H, Qin Y, Guan H, Lou F, et al: Frequent mutations in
EGFR, KRAS and TP53 genes in human lung cancer tumors detected by
ion torrent DNA sequencing. PLoS One. 9:e952282014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Wang Y, Wang M, Wang Q, Geng Z and Sun M:
Incidence and risk of infections associated with EGFR-TKIs in
advanced non-small-cell lung cancer: A systematic review and
meta-analysis of randomized controlled trials. Oncotarget.
8:29406–29415. 2017.PubMed/NCBI
|
|
12
|
Pao W, Miller V, Zakowski M, Doherty J,
Politi K, Sarkaria I, Singh B, Heelan R, Rusch V, Fulton L, et al:
EGF receptor gene mutations are common in lung cancers from ‘never
smokers’ and are associated with sensitivity of tumors to gefitinib
and erlotinib. Proc Natl Acad Sci USA. 101:13306–13311. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Toyooka S, Kiura K and Mitsudomi T: EGFR
mutation and response of lung cancer to gefitinib. N Engl J Med.
352:21362005. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Mitsudomi T, Morita S, Yatabe Y, Negoro S,
Okamoto I, Tsurutani J, Seto T, Satouchi M, Tada H, Hirashima T, et
al: Gefitinib versus cisplatin plus docetaxel in patients with
non-small-cell lung cancer harbouring mutations of the epidermal
growth factor receptor (WJTOG3405): An open label, randomised phase
3 trial. Lancet Oncol. 11:121–128. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Subramanian J, Morgensztern D, Goodgame B,
Baggstrom MQ, Gao F, Piccirillo J and Govindan R: Distinctive
characteristics of non-small cell lung cancer (NSCLC) in the young:
A surveillance, epidemiology, and end results (SEER) analysis. J
Thorac Oncol. 5:23–28. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Xu J, He J, Yang H, Luo X, Liang Z, Chen
J, Cai Z, Xu J and Ren-Heidenreich L: Somatic mutation analysis of
EGFR, KRAS, BRAF and PIK3CA in 861 patients with non-small cell
lung cancer. Cancer Biomark. 10:63–69. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Zhang L, Yang H, Zhao Y, Liu W, Wu S, He
J, Luo X, Zhu Z, Xu J, Zhou Q and Ren-Heidenreich L: Detection of
EGFR somatic mutations in non-small cell lung cancer (NSCLC) using
a novel mutant-enriched liquidchip (MEL) technology. Curr Drug
Metab. 13:1007–1011. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Kim TJ, Park CK, Yeo CD, Park K, Rhee CK,
Kim J, Kim SJ, Lee SH, Lee KY and Yoon HK: Simultaneous diagnostic
platform of genotyping EGFR, KRAS, and ALK in 510 Korean patients
with non-small-cell lung cancer highlights significantly higher ALK
rearrangement rate in advanced stage. J Surg Oncol. 110:245–251.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Tokumo M, Toyooka S, Kiura K, Shigematsu
H, Tomii K, Aoe M, Ichimura K, Tsuda T, Yano M, Tsukuda K, et al:
The relationship between epidermal growth factor receptor mutations
and clinicopathologic features in non-small cell lung cancers. Clin
Cancer Res. 11:1167–1173. 2005.PubMed/NCBI
|
|
20
|
Sahoo R, Harini V, Babu V, Okaly Patil GV,
Rao S, Nargund A, Venkataswamy E, Rao R and Kumar BS: Screening for
EGFR mutations in lung cancer, a report from India. Lung Cancer.
73:316–319. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Xie G, Xie F, Wu P, Yuan X, Ma Y, Xu Y, Li
L, Xu L, Yang M and Shen L: The mutation rates of EGFR in non-small
cell lung cancer and KRAS in colorectal cancer of Chinese patients
as detected by pyrosequencing using a novel dispensation order. J
Exp Clin Cancer Res. 34:632015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Ullrich A and Schlessinger J: Signal
transduction by receptors with tyrosine kinase activity. Cell.
61:203–212. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Sequist LV, Bell DW, Lynch TJ and Haber
DA: Molecular predictors of response to epidermal growth factor
receptor antagonists in non-small-cell lung cancer. J Clin Oncol.
25:587–595. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Lynch TJ, Bell DW, Sordella R,
Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat
SM, Supko JG, Haluska FG, et al: Activating mutations in the
epidermal growth factor receptor underlying responsiveness of
non-small-cell lung cancer to gefitinib. N Engl J Med.
350:2129–2139. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Oxnard GR, Arcila ME, Chmielecki J,
Ladanyi M, Miller VA and Pao W: New strategies in overcoming
acquired resistance to epidermal growth factor receptor tyrosine
kinase inhibitors in lung cancer. Clin Cancer Res. 17:5530–5537.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Ohashi K, Sequist LV, Arcila ME, Moran T,
Chmielecki J, Lin YL, Pan Y, Wang L, de Stanchina E, Shien K, et
al: Lung cancers with acquired resistance to EGFR inhibitors
occasionally harbor BRAF gene mutations but lack mutations in KRAS,
NRAS, or MEK1. Proc Natl Acad Sci USA. 109:E2127–E2133. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Engelman JA and Jänne PA: Mechanisms of
acquired resistance to epidermal growth factor receptor tyrosine
kinase inhibitors in non-small cell lung cancer. Clin Cancer Res.
14:2895–2899. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Engelman JA, Mukohara T, Zejnullahu K,
Lifshits E, Borrás AM, Gale CM, Naumov GN, Yeap BY, Jarrell E, Sun
J, et al: Allelic dilution obscures detection of a biologically
significant resistance mutation in EGFR-amplified lung cancer. J
Clin Invest. 116:2695–2706. 2006. View
Article : Google Scholar : PubMed/NCBI
|
|
29
|
Tam IY, Leung EL, Tin VP, Chua DT, Sihoe
AD, Cheng LC, Chung LP and Wong MP: Double EGFR mutants containing
rare EGFR mutant types show reduced in vitro response to gefitinib
compared with common activating missense mutations. Mol Cancer
Ther. 8:2142–2151. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Stamos J, Sliwkowski MX and Eigenbrot C:
Structure of the epidermal growth factor receptor kinase domain
alone and in complex with a 4-anilinoquinazoline inhibitor. J Biol
Chem. 277:46265–46272. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Michalczyk A, Klüter S, Rode HB, Simard
JR, Grütter C, Rabiller M and Rauh D: Structural insights into how
irreversible inhibitors can overcome drug resistance in EGFR.
Bioorg Med Chem. 16:3482–3488. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Cross DA, Ashton SE, Ghiorghiu S, Eberlein
C, Nebhan CA, Spitzler PJ, Orme JP, Finlay MR, Ward RA, Mellor MJ,
et al: AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated
resistance to EGFR inhibitors in lung cancer. Cancer Discov.
4:1046–1061. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Liu B, Bernard B and Wu JH: Impact of EGFR
point mutations on the sensitivity to gefitinib: Insights from
comparative structural analyses and molecular dynamics simulations.
Proteins. 65:331–346. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Balius TE and Rizzo RC: Quantitative
prediction of fold resistance for inhibitors of EGFR. Biochemistry.
48:8435–8448. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Martínez-Jiménez F, Overington JP,
Al-Lazikani B and Marti-Renom MA: Rationally designed drug blending
as a mechanism to overcome drug resistance in cancer: An
application in EGFR. http://sgt.cnag.cat/www/presentations/files/slides/20150709_Fran_Cancer_poster.pdfMarch
27–2017
|
